About Orbital Therapeutics
Orbital Therapeutics is a Healthcare company based in Yellow Springs (United States) founded in 2022, and was acquired by Bristol-Myers Squibb in October 2025. Distributor of RNA medicines. Orbital Therapeutics has raised $270 million across 1 funding round from investors including ARE, Exor and Arch Venture Partners. Its chief executive, as recorded, is Ron Philip. Orbital Therapeutics offers products and services including RNA Medicines Platform and State-of-the-Art Technologies. Its focus areas include Pharmaceutical Distributors and Specialty Drugs. Its competitors include Cardinal Health, Harrow and FFF Enterprises.
Company details
Orbital Therapeutics, backed by 270000000.0 from Arch Venture Partners, Andreessen Horowitz, Newpath Partners, ADG, Redmile Group, Exor, Invus, Moore Ventures, IGlobe Partners, Casdin Capital, Agent Capital, Alexandria, Heritage Medical Systems, focuses on providing healthcare solutions, pharmaceutical distributors, and specialty drugs. Distributor of RNA medicines. Driving innovation, growth, and excellence in its industry sectors.
- Headquarters Yellow Springs, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website orbitaltx.com
- Social LinkedIn
- Acquired by Bristol-Myers Squibb (Oct 2025)
- Total Equity Funding$270M (USD)
in 1 rounds
- Latest Funding Round$270M (USD), Series A
Apr 2023
- InvestorsARE
& 13 more
- Acquired byBristol-Myers Squibb
(Oct 2025)
Products & Services of Orbital Therapeutics
Orbital Therapeutics offers a comprehensive portfolio of products and services, including RNA Medicines Platform and State-of-the-Art Technologies.
Platform for designing RNA medicines tailored to specific diseases
Tools for calibrating RNA expression and tissue distribution in medicines
Funding Insights of Orbital Therapeutics
Orbital Therapeutics has successfully raised a total of $270M through 1 strategic funding round. The most recent funding activity was a Series A round of $270 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $270M
- Total Rounds 1
- Last Round Series A — $270M
- First Round $270M
(Apr 2023)
- Investors Count 13
All 1 funding rounds of Orbital Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $270M | Series A | – | Arch Venture Partners |
14 investors in total: 14 institutional.
Investors in Orbital Therapeutics
Orbital Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Exor and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Investment management services are offered by Newpath Partners. | newpath.partners | Boston, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Investments are focused on agtech, renewable energy, and transportation sectors. | moore-ventures.com | Los Angeles, United States | ||
Tech and life Science focused early stage VC firm investing in the US | iglobepartners.com | Singapore, Singapore | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Agent Capital is focused on healthcare venture capital investments. | agentcapital.com | Waltham, United States | ||
Private, public equities, hedge, and venture capital investments are managed. | adg.ae | Abu Dhabi, United Arab Emirates | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States |
Investor details for Orbital Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Orbital Therapeutics
21 people are tracked at Orbital Therapeutics (13 in leadership, 8 in team).
| Name | Role | Group |
|---|---|---|
Ron Philip | Chief Executive Officer | Leadership |
Robert Blakemore, Ph.D. | Associate Director, Mrna Sciences | Leadership |
Mark Doucette | Vice President, Controller | Leadership |
Jonathan Piazza | Chief Financial Officer | Leadership |
Matthew Nelson | Vp, Fp&a | Leadership |
Gilles BESIN | Chief Scientific Officer | Leadership |
Giuseppe Ciaramella | Co-founder | Leadership |
Benjamin Holmes | Director of Data Sciences | Leadership |
Tracey Cole | Director, Business Operations | Leadership |
Kristen Ott | Director Of RNA Sciences | Leadership |
Paloma Giangrande | Senior Vice President Discovery & Translational Biology | Leadership |
SHIVA ANAND | Associate Director, Lab Operations | Leadership |
Ju Li | Analytical Head | Leadership |
Molly McLaughlin | Senior Research Associate | Team |
Gabriel Peixoto | Principal Research Associate | Team |
Andrea Silva | Senior Research Associate | Team |
Margaux Audett | Scientist II | Team |
Mark Sabol | Research Associate II | Team |
Diego Vargas Blanco, Ph.D. | Scientist II | Team |
Arjan Vermeulen | Senior Scientist 1 | Team |
1 more people are available in the full profile.
Complete people profiles for Orbital Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Orbital Therapeutics
3 dated milestones of Orbital Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Orbital Therapeutics is founded.
- Funding First funding round of $270.0M.
- Exit Acquired by Bristol-Myers Squibb.
Competitors of Orbital Therapeutics
Orbital Therapeutics has 3 listed competitors in our database. They include Cardinal Health, Harrow and FFF Enterprises.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cardinalhealth.com | 1971 | Dublin, United States | 48,900 | Multiple healthcare products and services are provided to organizations. | ||
| harrow.com | 2012 | Nashville, United States | 315 | Ophthalmic products marketing services are provided by Harrow. | ||
| fffenterprises.com | 1988 | Los Angeles, United States | 486 | Distributes critical-care pharmaceuticals, vaccines, and specialty products to healthcare providers. |
Detailed competitors of Orbital Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Orbital Therapeutics
The website of Orbital Therapeutics (orbitaltx.com) receives about 4.8K visits a month and ranks #3,933,569 among all websites worldwide, #4,973 in Biotechnology and Pharmaceuticals.
- Monthly visits4.8K
▼ 2.5% vs previous month
- Unique visitors2.1K
per month
- Global rank#3,933,569
among all websites
- Category rank#4,973
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.6
- Average visit12 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Orbital Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| endpts.com | 100% | 8.4K | #3,077,209 | View details | |
| fiercebiotech.com | 80% | 858.3K | #81,022 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Orbital Therapeutics (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orbital Therapeutics
Complete news archive for Orbital Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orbital Therapeutics
Orbital Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Orbital Therapeutics is headquartered in Yellow Springs, United States. It is registered at Yellow Springs, Ohio, United States.
Ron Philip is the CEO of Orbital Therapeutics, as recorded in our data.
Orbital Therapeutics is a funded company, having raised a total of $270M across 1 funding round to date. The company's 1st funding round was a Series A of $270M, raised on Apr 2023.
Orbital Therapeutics, backed by 270000000.0 from Arch Venture Partners, Andreessen Horowitz, Newpath Partners, ADG, Redmile Group, Exor, Invus, Moore Ventures, IGlobe Partners, Casdin Capital, Agent Capital, Alexandria, Heritage Medical Systems, focuses on providing healthcare solutions, pharmaceutical distributors, and specialty drugs. Distributor of RNA medicines. Driving innovation, growth, and excellence in its industry sectors.
Orbital Therapeutics's top competitors include Cardinal Health, Harrow and FFF Enterprises.
Orbital Therapeutics offers RNA Medicines Platform and State-of-the-Art Technologies.
Orbital Therapeutics has 14 investors. Key investors include ARE, Exor, Arch Venture Partners, Bristol-Myers Squibb, and Andreessen Horowitz.
Yes. Orbital Therapeutics was acquired by Bristol-Myers Squibb in October 2025.